Company

Arno Therapeutics

As of the edition of 20 October 2026, Arno Therapeutics runs 3 drugs; it is on route A at 2 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Went quiet2
Stopped1
Total3

Where it needs a new molecule

Route A at 2 targets, route B at 0 targets.

Three of its 2 rows, by target and route
TargetRoute
TOP1 DNA topoisomerase 1Route A
PDPK1 3-phosphoinositide-dependent protein kinase 1Route A

All 2 rows on route A or B

In the product

2 company-target rows on route A or B; 0 are not shown here, and no score is.

Where its trials are

  • Cancer: 5 trials led
  • Blood and lymph: 2 trials led
  • Pregnancy and women's health: 2 trials led